Issue 8, 2010

Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation

Abstract

A new prodrug of gemcitabine, based on the covalent coupling of squalene to gemcitabine (GemSQ), has been designed to enhance the anticancer activity of gemcitabine, a nucleoside analogue active against a wide variety of tumors. In the present study, the feasibility of encapsulating GemSQ into liposomes either PEGylated or non-PEGylated has been investigated. The in vivo anticancer activity of these formulations has been tested on subcutaneous grafted L1210wt leukemia model and compared to that of free gemcitabine. The liposomal GemSQ appears to be a potential delivery system for the effective treatment of tumors.

Graphical abstract: Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation

Article information

Article type
Paper
Submitted
16 Feb 2010
Accepted
27 Apr 2010
First published
05 Jul 2010

Nanoscale, 2010,2, 1521-1526

Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation

B. Pili, L. H. Reddy, C. Bourgaux, S. Lepêtre-Mouelhi, D. Desmaële and P. Couvreur, Nanoscale, 2010, 2, 1521 DOI: 10.1039/C0NR00132E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements